此 乃 要 件 請 即 處 理 閣下如對本通函任何方面或應採取之行動有疑問，應諮詢持牌證券交易商、銀行經理、律師、專業會 計師或其他專業顧問。 閣下如已將名下全部中基長壽科學集團有限公司股份售出或轉讓，應立即將本通函及隨附之代表委 任表格送交買主或承讓人，或經手買賣或轉讓之銀行、持牌證券交易商或其他代理商，以便轉交買主 或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通函全部或任何部分內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 本公司謹訂於二零二五年六月二十七日（星期五）上午十時三十分假座香港九龍灣臨澤街8號啟匯30樓 舉行股東周年大會，召開大會之通告載於本通函第14至18頁。 無論 閣下能否出席大會，務請按照隨附代表委任表格上印備之指示將表格填妥，並盡快及無論如 何最遲於大會或其任何續會舉行時間48小時前，交回本公司之香港股份過戶登記分處香港中央證券 登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓。填妥及交回代表委任表格 後， 閣下仍可依願親身出席大會或其任何續會，並於會上表決。 Z ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本通告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited （於百慕達註冊成立之有限公司） 中基長壽科學集團有限公司 （股份代號：767） 股東周年大會通告 「有關期間」指由本決議案通過當日起至下列最早時限止期間： (a) 本公司下屆股東周年大會結束； – 2 – 4. 作為特別事項，考慮並酌情以普通決議案方式通過以下決議案： (A)「動議： (i) 在本決議案(iii)分段之規限下，一般及無條件批准董事於有關期間（定 義見下文）內，按照所有適用法例及本公司之經修訂及經重列的公司細 則並在其規限下行使本公司一切權力，以配發、發行及處理本公司股 本中每股面值0.01港元之額外股份，並作出或授出將要或可能須行使有 關權力之要約、協議及購股權（包括可轉換為本公司股份之認股權證、 債券及債權證）； (ii) 本決議案(i)分段所述之批准，將授權董事於有關期間內作出或授出將 要或可能須於有 ...

一致性：本報告在適合的情況下對公開範圍和計算方法發生變化的數據進行描述。 報告語言 本報告以繁體中文及英文版本發佈。本報告內容如有任何歧義，以中文版為準。本報告的電子版可通過聯交所網站進 行閱讀和下載。 1. 關於本報告 中基長壽科學集團有限公司（下稱「本公司」）及其附屬公司（下稱「本集團」或「我們」）已按照香港聯合交易所有限公司 （「聯交所」）《證券上市規則》附錄C2 —《環境、社會及管治報告指引》（下稱「《指引》」）的披露責任編製環境、社會及管 治（下稱「環境、社會及管治」）報告（下稱「本報告」）。本報告總結二零二四年一月一日至二零二四年十二月三十一日 止年度（下稱「二零二四年度」或「報告期」）有關本集團環境、社會及管治方面的行動及量化表現，亦是與持份者建立 及保持良好關係的溝通管道之一。有關管治方面的資訊，可透過本集團二零二四年度年報中的「企業管治報告」章節了 解。 報告範圍 本集團管理層根據重要性原則對報告範圍進行討論、識別及確認，並考慮核心業務及主要收益來源。由於本集團的主 要的營運據點為本集團的香港辦公室，其運作對本集團在環境方面的關鍵績效指標（「關鍵績效指標」）有重大影響，因 此本報告中的環境方 ...

Financial Performance - For the year ended December 31, 2024, the revenue was HK$166,181,000, a significant increase of 156% compared to HK$64,989,000 in 2023[15]. - The loss attributable to the owners of the Company for 2024 was HK$34,726,000, compared to a profit of HK$2,313,000 in 2023[15]. - As of December 31, 2024, total shareholders' equity was HK$400,139,000, down from HK$430,465,000 in 2023, representing a decrease of approximately 7%[18]. - The Group recorded total revenue of approximately HK$166.2 million for FY2024, a significant increase from HK$65.0 million in FY2023, while incurring a loss of approximately HK$34.8 million compared to a profit of HK$2.5 million in the previous year[53]. - The basic and diluted loss per share for FY2024 was approximately HK$4.15 cents, compared to earnings per share of HK$0.15 cents in FY2023[54]. - As of December 31, 2024, the consolidated net assets of the Group were approximately HK$400.1 million, a decrease from HK$430.5 million in FY2023[54]. - The Group's cash and cash equivalents decreased to approximately HK$47,842,000 as of December 31, 2024, down from HK$81,075,000 as of December 31, 2023[99]. - The Group's gearing ratio as of December 31, 2024, was approximately 2.9%, an increase from 2.1% as of December 31, 2023[165]. Longevity Science Business - The Company is focused on becoming a world-leading platform for global cellular medical sciences across the entire industry chain[20]. - The Company aims to optimize resource allocation and strengthen core competitiveness in the longevity science business[20]. - The Company has made steady progress in advancing its strategic plans amid a recovering global economy[20]. - The Chairman emphasized the commitment to establishing a world-leading platform for the transformation and application of longevity science[20]. - In 2024, the longevity biological products segment achieved significant sales revenue growth, driven by optimized research, development, and production processes, as well as market expansion through joint ventures and mergers[22][25]. - The longevity management sector has enhanced service quality and established longevity management centers in major cities, with early successes noted in Hong Kong and Shenzhen, contributing to the brand's growing influence in high-quality health services[23][25]. - The longevity science business contributed approximately HK$142.0 million in revenue for FY2024, but reported a segment loss of approximately HK$17.6 million[53]. - The revenue from the longevity science segment amounted to approximately HK$142,016,000 for FY2024, a significant increase from HK$31,326,000 in FY2023[77]. - Approximately HK$39,605,000 of the revenue in the longevity science segment was generated from diagnostic consultation and medical testing, while HK$102,411,000 was from sales of longevity biological products[77]. - The segment incurred a loss of approximately HK$17,559,000 in FY2024, an improvement from a loss of HK$24,016,000 in FY2023, indicating a positive trend despite ongoing challenges[81]. Money Lending and Financial Advisory Business - The money lending and financial advisory business is recovering steadily, although market constraints on secured home loans persist due to subdued property transactions in the PRC[35]. - The money lending and financial advisory business generated static revenue of approximately HK$24.2 million in FY2024, down from HK$33.7 million in FY2023, but increased segment profit to approximately HK$34.4 million from HK$25.4 million[58]. - The Group's strategic partners in the money lending business include FOTIC, Fanhua, and Haier, with ongoing negotiations to monetize portions of the loan portfolio[61]. - The average loan size for first mortgages under FOTIC and ShanXi was approximately RMB0.86 million, with interest rates ranging from 8.4% to 19.2% for FY2024[120][124]. - The average loan size for first and second mortgages under Fanhua and Haier was approximately RMB0.2 million, with interest rates ranging from 12% to 18% for FY2024[124]. - The Group's strategic partners loan assets were accounted as other receivables for approximately HK$172,917,000 before impairments as of December 31, 2024[127]. - The top five borrowers accounted for approximately 89.19% of the total loan and interest receivables of the Group as of December 31, 2024, an increase from 79.93% in 2023[134]. - The Group is required to maintain a risk provision top-up fund equivalent to 20-30% of the initial loan principals borrowed by customers referred to Fanhua and Haier[117]. - The Group earns various fees including loan origination fees, management service fees, recovery fees, and accrued interest income from strategic partners[119]. Operational Challenges and Strategic Initiatives - The Company faced operational challenges due to a license revocation by the Hong Kong Department of Health, resulting in the loss of past rental expenses and capital expenditures[47]. - The Company has restructured its operations and restored business partnerships following a police investigation into former employees, which was confirmed to be unrelated to the company itself[36]. - The Group is focusing on expanding its longevity science business through membership programs and distribution channels, targeting anti-cancer, anti-aging, and knee joint health products[50]. - The Group's approach to the money lending business has been prudent due to a sluggish sentiment in the PRC property market, resulting in a static performance[52]. - The Group plans to continue monitoring market conditions to seek suitable tenants for stable rental income or consider disposing of investment properties for capital appreciation[86]. - The Group has initiated recovery actions on previously impaired loans, indicating a proactive approach to asset management[134]. Corporate Governance and Management - The Company has a diverse board with members holding significant experience in innovation, finance, and corporate governance, enhancing strategic decision-making capabilities[195][196][197][200]. - The board's composition includes professionals with backgrounds in healthcare, investment, and media, indicating a multifaceted approach to market expansion and product development[195][196][200]. - The Company is focused on leveraging the expertise of its directors to drive growth and explore new market opportunities[195][196][197][200]. - The presence of directors with international experience suggests potential for global partnerships and collaborations in future projects[195][196][200]. - The board's commitment to risk management and governance is reflected in the establishment of various committees, including audit and remuneration[197][199]. Future Outlook and Strategic Plans - Looking ahead to 2025, the company aims to become the "Global Leader in Longevity Science," focusing on technology leadership, innovation-driven growth, and global expansion while increasing investment in research and development[28][31]. - The company plans to integrate AI with longevity technology by establishing an AI longevity technology joint laboratory, aiming for early disease prediction and personalized health management solutions[29][31]. - The Group plans to operate under a light asset model to reduce operational pressure and risk while expanding its longevity science business through potential joint ventures[177]. - The company aims to enhance its position in the longevity science and biomedical sectors through strategic investments and expansions[182][183].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 另茲提述本公司日期為二零二三年十二月十一日之澄清公告（「澄清公告」），內容有 關（其中包括）日期為二零二三年十二月九日的若干媒體報導，指衛生署（「衛生署」） 轄下私營醫療機構規管辦公室（「規管辦公室」）以規管辦公室對本公司提出的指控為 由，吊銷中基長壽科學集團有限公司的日間醫療中心牌照（「日間醫療中心牌照」）， 自二零二三年十二月九日起生效，有關指控如下： (i) 管有及涉嫌使用無牌X光機；及 (ii) 本公司日間醫療中心處理涉嫌未經註冊之藥劑製品； (iii) 妨礙或阻延衞生署獲授權人員執行其職能。 – 1 – Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 內幕消息 衛生署對本公司轄下中基長壽日間醫療中心處理之 最新進展 本公告由中基長壽科學集團有限公司（「本公司」）董事（「董事」）會 ...

Group 1 - The company, Zhongji Changshou Science, announced a joint venture agreement with Huali (Guangdong) Life Science Technology Co., Ltd. to establish a joint venture in China, with Zhongji Health holding 51% and Huali Life holding 49% of the equity [1] - The initial registered capital of the joint venture is set at RMB 1 million, which will be contributed by both parties according to their respective equity ratios [1] - The joint venture aims to provide longevity health services in China, capitalizing on the growing demand from affluent customers willing to invest in longevity science applications to enhance their overall health and immune status [1] Group 2 - The establishment of the joint venture aligns with the company's strategic development plan in the longevity science sector and is expected to benefit future business growth [2] - The joint venture will create a leading life science industry empowerment platform, integrating academic conferences, technology transfer, and industrial implementation into a cohesive ecosystem [2] - The board believes that the joint venture will enhance the company's positioning in the longevity science diagnostics and medical services field, opening new revenue sources for long-term stable and sustainable growth [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 成立合資公司之 自願公告 本公告由中基長壽科學集團有限公司（「本公司」）自願作出。 合資協議訂約各方之資料 本公司為於百慕達註冊成立的有限公司，為一間投資控股公司，透過其附屬公司主 要從事長壽科學業務、借貸與金融投資諮詢，以及證券、物業及投資業務。中基健 康為一家於中國成立的有限公司，主要從事提供健康長壽管理服務及健康長壽產品 的生產和銷售。 華驪生命是一家於二零二二年於中國成立的有限公司。華驪生命作為中國首屈一指 的，以「會議驅動產業生態」為核心發展模式的創新型科技企業，專注於通過「造 會、辦會、轉化」的全鏈閉環運營體系，重塑生命科學領域資源的流通與整合效率， 而且在舉辦長壽大健康展會等領域有著豐富的經驗，客戶資源豐富，成功舉辦了多 場在生 ...

Financial Performance - For the fiscal year ending December 31, 2024, the group's revenue increased by approximately 155.4% to about HKD 166.2 million, compared to HKD 65.0 million in the fiscal year 2023[5] - The group's gross profit for the fiscal year 2024 rose by approximately 2.0% to about HKD 57.4 million, compared to HKD 56.3 million in the fiscal year 2023[5] - The group recorded a post-tax loss of approximately HKD 34.8 million for the fiscal year 2024, compared to a post-tax profit of approximately HKD 2.5 million in the fiscal year 2023[5] - Total revenue for the year ended December 31, 2024, reached HKD 166,181,000, a significant increase from HKD 64,989,000 in 2023, representing a growth of approximately 156%[34] - The company reported a pre-tax profit of HKD 4,745,000 for the year ended December 31, 2024, compared to a loss in the previous year[34] - The group reported a net loss of approximately HKD 34.80 million in fiscal year 2024, compared to a profit of HKD 2.52 million in fiscal year 2023[69] Assets and Liabilities - The group's net assets decreased by 7.0% to HKD 400.1 million in the fiscal year 2024, down from HKD 430.5 million in 2023[5] - The total liabilities for the group increased significantly, with current liabilities totaling HKD 121.7 million in 2024, compared to HKD 73.3 million in 2023[10] - The group's cash and cash equivalents decreased to HKD 47.8 million in 2024 from HKD 81.1 million in 2023[10] - The total assets of the company as of December 31, 2024, were HKD 525,631,000, an increase from HKD 509,254,000 in 2023[29] - As of December 31, 2024, the group recorded net current assets of approximately HKD 372,047,000, an increase from HKD 250,127,000 in the fiscal year 2023[89] Revenue Segmentation - For the fiscal year ending December 31, 2024, the company reported segment revenues of HKD 142,016,000 from longevity science, HKD 24,165,000 from lending and financial consulting, totaling HKD 166,181,000[25] - Revenue from health and medical product sales was HKD 102,411,000 in 2024, compared to HKD 4,447,000 in 2023, indicating a substantial increase[34] - Major clients contributed significantly to revenue, with Client B generating HKD 65,650,000 and Client C contributing HKD 32,900,000 in 2024[32] - The lending and financial consulting segment recorded revenue of approximately HKD 24.17 million in fiscal year 2024, down from HKD 33.66 million in fiscal year 2023[71] Operational Developments - The company plans to expand its longevity science business by starting sales and distribution of longevity wine in 2024[22] - The company is actively expanding its longevity management services, establishing centers in major global cities like Hong Kong and Shenzhen, enhancing brand influence and service quality[56] - The strategic shift towards supply chain finance in the longevity science sector has improved operational quality and efficiency, reducing business risks[54] - The company plans to increase R&D investment and promote technological innovation in longevity science, aiming to solidify its position as a global leader by 2025[56] Challenges and Risks - The company is navigating challenges in the lending and financial consulting business due to a sluggish real estate market and regulatory changes impacting mortgage demand[59][60] - A strategic partnership with law firms has been initiated to expedite the recovery of overdue loans, involving significant operational efforts[62] - The expected credit loss model led to a significant impairment loss of HKD 15,938,000 in 2024, compared to a reversal of HKD 5,699,000 in 2023[36] Shareholder Returns and Dividends - The group did not recommend a final dividend for the fiscal year 2024, consistent with the fiscal year 2023[5] - The basic and diluted loss per share attributable to the owners of the company for the year ending December 31, 2024, is (HKD 34,726) thousand, compared to a profit of HKD 2,313 thousand in 2023[43] - The board of directors remains committed to shareholder returns, with plans to increase dividends by 10% in the next fiscal year[124] Corporate Governance - The audit committee has reviewed and approved the consolidated financial statements for the fiscal year 2024, ensuring compliance with applicable accounting standards and regulations[119] - The company has adopted the corporate governance code and has complied with applicable provisions during the fiscal year 2024[116] Future Outlook - The company is optimistic about the growth potential of its longevity science business despite recent challenges, including a significant marketing cost of HKD 9,000,000 related to NMN products[82] - The company is exploring potential acquisitions to strengthen its market position, with a budget of $200 million allocated for this purpose[124] - The company projects a revenue guidance of $500 million for Q2 2025, reflecting a 20% growth from Q1 2025[124]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited （於百慕達註冊成立之有限公司） 中基長壽科學集團有限公司 部門、以及增強提供診斷及醫學檢測服務的服務線及本集團銷售的其他保健品產品 線的業務而產生與長壽科學業務相關的重大重組成本。 於本公告日期，本公司尚在落實二零二四財年的年度業績。因此，本公告所載資料 僅基於對董事會於本公告日期的最新可得資料及本集團二零二四財年的未經審核綜 合管理賬目作出的初步評估，有關賬目尚未經本公司核數師或董事會審核委員會確 認、審核或審閱。本集團二零二四財年的實際業績或會與本公告所披露者有所出 入，且須待最終審閱及╱或作出必要調整。本集團二零二四財年的財務業績詳情預 計將於二零二五年三月二十八日或之前在本公司年度業績公告中公佈。 本公司股東及潛在投資者在買賣本公司股份時，務請審慎行事。 承董事會命 （股份代號：767） 本公告由中基長壽科學集團 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 於本公告日期，董事如下： 執行董事 閆立先生 （主席） 閆一帆先生 （行政總裁） 李小雙先生 曹衆女士 獨立非執行董事 李思先生 黃江先生 黃慈波教授 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 董事會會議日期 中基長壽科學集團有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此宣佈，本 公司將於二零二五年三月二十八日（星期五）舉行董事會會議，以考慮及批准（其中 包括）本公司及其附屬公司截至二零二四年十二月三十一日止年度之全年業績及派 發末期股息（如有），以及處理其他事項。 承董事會命 中基長壽科學集團有限公司 主席 閆立 香港，二零二五年三月十八日 – 1 – 非執行董事 何亦武博士 呂長勝先生 本公告之中英文本如有任何歧義，概以英文本為準。 – 2 – ...